Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Point Therapeutics has provided encouraging preliminary results from the phase II trial of its drug talabostat plus gemcitabine in pancreatic cancer and is now advancing the study to completion.
Subscribe to our email newsletter
Of the patients who entered the study, 48% have survived more than six months. To date, 9.7% have demonstrated a clinical response to treatment, including one complete response and two partial responses. One patient with disease to the liver experienced a complete response to treatment, defined as the complete disappearance of tumor.
“Point has demonstrated preclinically that talabostat is a potent inhibitor of fibroblast activation protein (FAP), an enzyme that is highly expressed in pancreatic cancer and is believed to promote tumor growth. In addition, preclinical work combining talabostat with gemcitabine has also demonstrated encouraging results,” said Dr George Demetri, a member of Point’s Clinical Advisory Board.
The primary endpoint of the trial is six-month survival. Secondary study endpoints include overall survival, progression-free survival, quality of life, and performance status. Final results from the study are expected mid-year 2007.